ReviewDrug safety2005
The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.
Review in Drug safety, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 84 citations in OpenAlex.
- Voriconazole greatly increases the exposure to oral buprenorphine.European journal of clinical pharmacology · 2018Trial
- Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.European journal of clinical pharmacology · 2016Trial
- Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.European journal of clinical pharmacology · 2015Trial
- Rifampicin markedly decreases the exposure to oral and intravenous tramadol.European journal of clinical pharmacology · 2013Trial
- Evaluation ofJournal of dietary supplements · 2026Article
- Influence of probiotics and deoxycholate on azathioprine transport in the PAMPA model: insights into pharmacomicrobiomics and interindividual variability in drug response.Frontiers in pharmacology · 2025Article
- Liposomal Copermeation Assay Reveals Unexpected Membrane Interactions of Commonly Prescribed Drugs.Molecular pharmaceutics · 2024Article
- A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel disease.United European gastroenterology journal · 2024Review
- Effect of High Altitude Environment on Pharmacokinetic and Pharmacodynamic of Warfarin in Rats.Current drug metabolism · 2024Article
- Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.Chest · 2022Review
- Multiple Molecular Mechanisms to Overcome Multidrug Resistance in Cancer by Natural Secondary Metabolites.Frontiers in pharmacology · 2021Review
- Rifaximin as a rare cause of rhabdomyolysis in cirrhosis.Clinical case reports · 2018Article
- A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Journal of clinical pharmacology · 2017Review
- Characterization of the mechanism of drug-drug interactions from PubMed using MeSH terms.PloS one · 2017Article
- Article
- Role of p-glycoprotein expression and function in cystinotic renal proximal tubular cells.Pharmaceutics · 2011Article
- New oral anticoagulants: a practical guide for clinicians.Journal of thrombosis and thrombolysis · 2010Review
- Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.Basic & clinical pharmacology & toxicology · 2009Article
- [Drug interactions in geriatric medicine].Wiener medizinische Wochenschrift (1946) · 2009Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of polytherapy in clinical practice necessitates an appreciation and understanding of the potential for drug interactions. Recent publications provide insight into the role of the active transport systems P-glycoprotein (P-gp) and human organic anion-transporting polypeptides (OATPs) in drug interactions. Active drug transporters influence the bioavailability of a number of drugs by controlling their movement into, and out of, cells. The active transport systems P-gp and OATP play an important role in drug elimination. The activity of these transport systems is controlled, in part, by genetic factors; however, drugs and foods also influence the activity of these systems. It appears that interference with P-gp or OATP, either as upregulation or inhibition, may affect plasma drug concentrations by altering intestinal absorption, proximal renal-tubular excretion or biliary excretion. Overall, the net bioavailability of a drug or substance is affected by the relative contributions of cellular efflux (P-gp) and influx (OATP) mechanisms and to what extent these systems are active during phases of uptake and absorption versus removal and excretion from the body. Many of the drugs and foods that affect active drug transport activity are known to interact with the cytochrome P450 enzyme system; therefore, the net effect of concomitant drug administration is complex. One must now consider the impact of metabolism (CYP-mediated drug biotransformation), P-gp-mediated drug efflux and OATP-mediated uptake when making assessments of drug absorption and distribution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.